TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pro Medicus Limited ( (AU:PME) ) has provided an announcement.
Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, Inc., has signed three new contracts valued at a minimum of A$29 million, expanding its presence in the healthcare imaging market. These contracts, which are cloud-based and transaction-oriented, involve a pediatric hospital, a cancer center, and a regional healthcare provider, highlighting the company’s adaptability across various segments. This development increases the company’s total contract value for the first half of FY26 to A$273 million, reinforcing its strong market position and future growth potential.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading healthcare informatics company founded in 1983. It provides a comprehensive range of medical imaging software and services to hospitals, imaging centers, and healthcare groups worldwide. The company’s Visage 7 suite offers an ultra-fast, clinically rich, and scalable platform that supports both public and private cloud environments. Pro Medicus also provides RIS, PACS, AI, and e-health solutions, making it a significant player in the healthcare imaging industry.
YTD Price Performance: 0.67%
Average Trading Volume: 170,664
Technical Sentiment Signal: Buy
Current Market Cap: A$26.27B
See more data about PME stock on TipRanks’ Stock Analysis page.